Destiny Pharma
plc
("Destiny
Pharma" or "the Company")
Last Day of Dealings on
AIM
Brighton, United Kingdom - 12 August
2024 - Destiny Pharma plc (AIM:
DEST), a clinical stage biotechnology company focused on the
development and commercialisation of novel medicines to prevent and
cure life-threatening infections, reminds shareholders that the
last day of trading in Destiny Pharma's ordinary shares on AIM is
today, 12 August 2024.
The cancellation of the admission of
the Company's ordinary shares to trading on AIM (the
"Cancellation") was originally announced on 15 July 2024 and was
approved by shareholders at the general meeting held on 31 July
2024.
The Cancellation will become
effective at 7:00 a.m. on 13 August 2024. Following
Cancellation, the Company will re-register as a
private company under the name Destiny Pharma
Limited.
Matched Bargain Facility Arrangements
The Company's ordinary shares will
be admitted to trading on the JP Jenkins securities matching
platform from 13 August 2024.
JP Jenkins provides a securities
matching venue for unlisted or unquoted assets in companies,
enabling shareholders and prospective investors to buy and sell
shares on a matched bargain basis. JP Jenkins is a trading name of
InfinitX Limited and Appointed Representative of Prosper Capital
LLP (FRN453007).
Shareholders wishing to trade these
securities can do so through their stockbroker. Trades will be
conducted at a level that JP Jenkins is able to match a willing
seller and a willing buyer. Trades can be conducted, and limits can
be accepted, during normal business hours. Shareholders or
potential investors can place limits via their existing UK
regulated stockbroker.
The indicative pricing for the
ordinary Shares (ISIN: GB00BDHSP575), as
well as the transaction history, will be available on the JP
Jenkins website at (https://jpjenkins.com/company/destinypharma).
Following Cancellation, shareholders
are encouraged to sign up to the Company's email news alerts via
the Destiny Pharma website to remain up to date with the Company's
developments.
Further details regarding the
Cancellation and re-registration are set out in the circular sent
to shareholders dated 15 July 2024. A copy of the circular is
available on the Company's website www.destinypharma.com
Following Cancellation, Shore
Capital will cease to act as nominated adviser and corporate broker
to the Company.
For
further information, please contact:
Destiny Pharma plc
Chris
Tovey, CEO
Shaun Claydon, CFO
+44 (0)1273 704 440
pressoffice@destinypharma.com
FTI
Consulting
Ben Atwell / Simon Conway
+44 (0) 203 727 1000
destinypharma@fticonsulting.com
Shore Capital (Nominated Adviser and Broker)
Daniel Bush / James Thomas / Lucy
Bowden
+44 (0) 207 408 4090
About Destiny Pharma
Destiny Pharma is an innovative,
clinical-stage biotechnology company focused on the development and
commercialisation of novel medicines that can prevent
life-threatening infections. The Company's drug development
pipeline includes two late-stage assets XF-73 Nasal gel, a
proprietary drug targeting the prevention of post-surgical
staphylococcal hospital infections including MRSA and NTCD-M3, a
microbiome-based biotherapeutic for the prevention of C. difficile
infection (CDI) recurrence which is the leading cause of hospital
acquired infection in the US.
For further information on the
company, please visit www.destinypharma.com.